DPP-4 inhibitors: What may be the clinical differentiators?

Abstract Attenuation of the prandial incretin effect, mediated by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), contributes to hyperglycemia in type 2 diabetes mellitus (T2DM). Since the launch of sitagliptin in 2006, a compelling body of evidence has accumulate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2010-11, Vol.90 (2), p.131-140
1. Verfasser:	Gerich, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - analogs & derivatives Adamantane - therapeutic use Blood Glucose - drug effects Blood Glucose - metabolism Diabetes Mellitus, Type 2 - drug therapy Dipeptides - therapeutic use Dipeptidyl Peptidase 4 - drug effects Dipeptidyl peptidase-4 Dipeptidyl-Peptidase IV Inhibitors - classification Dipeptidyl-Peptidase IV Inhibitors - therapeutic use DPP-4 Endocrinology & Metabolism Energy Intake Gastric Emptying - drug effects Gliptins GLP-1 Glucagon-Like Peptide 1 - therapeutic use Glycated Hemoglobin A - drug effects Glycated Hemoglobin A - metabolism Humans Hyperglycemia - prevention & control Hypoglycemic Agents - therapeutic use Incretins - physiology Incretins - secretion Intestinal Mucosa - drug effects Intestinal Mucosa - physiology Intestinal Mucosa - physiopathology Linagliptin Neurons - drug effects Neurons - physiology Nitriles - therapeutic use Piperidines - therapeutic use Purines - therapeutic use Pyrazines - therapeutic use Pyrrolidines - therapeutic use Quinazolines - therapeutic use Sitagliptin Phosphate Triazoles - therapeutic use Type 2 diabetes Uracil - analogs & derivatives Uracil - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!